NCT02091388 - Bioavailability of LY03004 and Risperdal® Consta® | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

LY03004

DRUG

Risperdal® Consta®

Trial Locations (10)

CRI LifeTree, Philadelphia

Comprehensive Clinical Development, Washington D.C.

CBH Health LLC, Rockville

Atlanta Center for Medical Research, Atlanta

Compass Research, Leesburg

Woodland International, Little Rock

Community Clinical Research Inc, Austin

Collaborative Neuroscience Network LLC, Long Beach

Neuropsychiatric Research Center of Orange County, Orange

CRI LifeTree, Marlton

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY